Valuation: Neurizon Therapeutics Limited

Capitalization 7.88Cr 5.18Cr 4.43Cr 4.12Cr 3.84Cr 7.09Cr 444.29Cr 49Cr 19Cr 208.03Cr 19Cr 19Cr 763.04Cr P/E ratio 2023
-3.88x
P/E ratio 2024 -9.42x
Enterprise value 6.8Cr 4.47Cr 3.82Cr 3.56Cr 3.31Cr 6.12Cr 383.77Cr 43Cr 16Cr 179.69Cr 17Cr 16Cr 659.1Cr EV / Sales 2023
6.39x
EV / Sales 2024 90.4x
Free-Float
79.71%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.03%
1 week+9.68%
Current month+6.25%
1 month+3.03%
3 months+70.00%
6 months+3.03%
More quotes
1 week 0.16
Extreme 0.155
0.17
1 month 0.16
Extreme 0.155
0.18
Current year 0.1
Extreme 0.096
0.18
1 year 0.1
Extreme 0.096
0.24
3 years 0.06
Extreme 0.06
0.54
5 years 0.06
Extreme 0.06
0.54
10 years 0.03
Extreme 0.03
0.54
More quotes
Manager TitleAgeSince
Chief Executive Officer - 01/09/2023
Director of Finance/CFO - 22/04/2025
Corporate Secretary - 24/05/2024
Director TitleAgeSince
Director/Board Member - 09/05/2024
Chairman - 17/05/2024
Director/Board Member - 31/05/2024
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+3.03%+9.68%-22.73%+86.81% 5.34Cr
+0.30%+1.58%-16.38%+145.93% 71TCr
-0.50%+0.57%+4.68%-10.57% 38TCr
-1.31%+1.67%+13.02%+26.49% 34TCr
-3.64%-2.74%-55.22%+8.36% 31TCr
-2.36%-1.23%+0.78%-21.03% 26TCr
-3.00%-1.93%-3.83%+18.13% 24TCr
-1.66%+1.10%-14.76%-4.83% 22TCr
-0.79%+3.00%-34.75%-11.10% 21TCr
-1.70%-1.00%-10.75%+19.50% 16TCr
Average -1.16%+0.42%-13.99%+25.77% 28.17TCr
Weighted average by Cap. -1.30%+0.36%-12.51%+39.06%
See all sector performances

Financials

2023 2024
Net sales 38.19L 25.11L 21.47L 20L 18.6L 34.37L 22Cr 2.4Cr 91.62L 10Cr 94.16L 92.22L 37Cr 8L 6L 5L 4L 4L 8L 4.75Cr 52.81L 20.19L 2.22Cr 20.75L 20.32L 8.15Cr
Net income -62.12L -40.83L -34.92L -32.52L -30.25L -55.89L -35Cr -3.9Cr -1.49Cr -16Cr -1.53Cr -1.5Cr -60Cr -76.73L -50.44L -43.13L -40.18L -37.37L -69.05L -43Cr -4.81Cr -1.84Cr -20Cr -1.89Cr -1.85Cr -74Cr
Net Debt -16.73L -11L -9L -9L -8L -15.05L -9.44Cr -1.05Cr -40.13L -4.42Cr -41.24L -40.39L -16Cr -1.07Cr -70.54L -60.32L -56.18L -52.25L -96.55L -61Cr -6.73Cr -2.57Cr -28Cr -2.65Cr -2.59Cr -103.94Cr
More financial data * Estimated data
Logo Neurizon Therapeutics Limited
Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.
Employees
4
More about the company
Date Price Change Volume
14/25/14 0.1700 $ +3.03% 4,20,595
11/25/11 0.1650 $ +3.13% 6,06,693
10/25/10 0.1600 $ 0.00% 87,230
09/25/09 0.1600 $ +3.23% 1,81,543
08/25/08 0.1550 $ 0.00% 2,06,928

Delayed Quote Australian S.E., July 14, 2025 at 11:05 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1650AUD
Average target price
0.4200AUD
Spread / Average Target
+154.55%
Consensus

Annual profits - Rate of surprise